Chugai Seiyaku Kabushiki Kaisha

Other

Shinshu University

National Hospital Organization

Tadamitsu Kishimoto

Kishimoto, Tadamitsu

Masahiko Mihara

Yoshiyuki Ohsugi

Yoichiro Moriya

Hiroshi Suzuki

Shigeto Kawai

Hiroharu Matsuoka

Yasuo Koishihara

Kenichi Akamatsu

Nobuaki Kato

Masaji Okada

Shin Shimaoka

Yasuhisa Takeda

Nobuhiro Ohi

Masafumi Takahashi

Keiichiro Tsuji

Atsushi Izawa

Katushito Miyamoto

Hiromichi Nishina

Yasuo c/o Chugai Seiyaku Kabushiki K Koishihara

A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising an interleukin-6 (IL-6) antagonist, for example an antibody directed against IL-6 receptor, an antibody directed against IL-6, an antibody directed against gp130, and the like.

Methods of treating a disease mediated by sensitized T cells

The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation.

Methods for suppressing acute rejection of a heart transplant

A therapeutic agent for solid tumors, the agent comprising as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence represented by SEQ ID NO:2 or an antibody fragment maintaining the antibody activity.

Therapeutic agents for solid tumors

The present invention provides a novel therapeutic agent for graft-versus-host disease (GVHD). A therapeutic agent for graft-versus-host disease (GVHD), which comprises an interleukin 6 (IL-6) receptor inhibitor as an active ingredient.

Method for suppressing the development of graft-versus-host-disease by administering interleukin 6 receptor antibodies

There is provided a synovial cell growth inhibitor, or a pharmaceutical composition for treatment of chronic rheumatoid arthritis based on the synovial cell growth inhibitor. The pharmaceutical composition for treatment of chronic rheumatoid arthritis or synovial cell growth inhibitor contains an IL-6 antagonist, such as IL-6 antibody or IL-6R antibody, as an effective component.

Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component

Pharmaceutical agents containing methotrexate derivative

Chronic rheumatoid arthritis therapy containing IL-6 antagonist as

Methotrexate derivative

Growing community of inventors

Gotenba, Japan

Masahiko Mihara